The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review

Abstract

ObjectiveThe aim of this study was to evaluate the impact of patent expiry on drug prices by means of a systematic literature review.MethodsA systematic literature search was performed in PubMed to identify all published literature on the impact of patent expiration on drug prices. Additional literature was identified using a less distinct syntax in Google Scholar and EconLit. Data extraction followed a standardized assessment form containing the domains study type, study aim, reported outcomes, number of drugs and drug classes assessed, and originators or generics assessed.ResultsThe 16 identified studies that assessed impact of patent expiry on drug prices showed that price developments after patent expiration varied between countries. The included studies assessed price developments for the USA, Canada, Australia, the UK, the Netherlands, Germany and France, Spain, Italy, Norway, Sweden and Denmark. The number of drugs included within different studies ranged between 1 and 219. The identified studies indicated that drug prices decreased significantly after patent expiry with drug price ratios ranging from 6.6 to 66% 1–5 years after patent expiry.ConclusionDrug prices decrease significantly after patent expiry. The extent of this price reduction varied greatly between products and countries. For this reason, country-specific analyses on price developments after patent expiry should be used when these are considered in decision making. Future research should be dedicated to gathering more country-specific data to reduce the uncertainty with regard to price developments.Electronic supplementary materialThe online version of this article (10.1007/s40258-018-0406-6) contains supplementary material, which is available to authorized users.

Financial Performance of SDG Mutual Funds Focused on Biotechnology and Healthcare Sectors

“…The cost of biopharmaceutical treatments is much higher than that of using small-molecule treatments [18,19], due to the large failure rates in clinical trials and the long development process period, both of them contributing to increasing the drug prices [20]. This disparity in drug prices decreases when the patent of biopharmaceutical products expires and similar biotherapeutic products appear in the market [21], while orphan drugs are too expensive to develop, requiring governments to provide firms with market exclusivity and public funding in order to recoup the firm's initial investments, to reduce the high financial costs taken on by firms, and to ensure fair and equal access to treatments by patients [17].…”

Sustainability of Pork Production with Immunocastration in Europe

“…At present, only one product for pigs is available on the European market (Improvac ® ), and the manufacturer has a monopoly in this segment. A review of Vondeling and co-authors [115] shows that pharmaceutical prices fall by 6.6-66% after patents expire. A recent study by Verhaagh and Deblitz [114] even estimated price reduction at 55%, based on historical discounts after patent expiration.…”

Technological Advancements in Monoclonal Antibodies

“…Therefore, country-specific analyses on the evolution of prices after the expiry of the patent are usually performed. These analyses are important for decision making regarding the research and production of these drugs [ 98 ]. Because they are versions of their reference biologicals, the production of biosimilars is usually cheaper because of the abbreviation in the clinical trial program, which directly impacts the achievement of a more advanced and efficient process.…”